ciclopirox and tacrolimus

ciclopirox has been researched along with tacrolimus in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Babij, CM; Lozza, G; Monopoli, A; Ongini, E; Parker, EM	1
Gupta, AK; Versteeg, SG	1
Amici, JM; Baricault, S; Barrel, A; Bechu, S; Benichou, J; Beylot-Barry, M; Bourseau-Quetier, C; Cailleux, HC; Chamaillard, M; Chosidow, O; De Preville, PA; Dore, MX; Gabison, G; Joly, P; Lair, G; Ly, S; Mion-Mouton, N; Richard-Lallemand, MA; Rossi, B; Rzeznik, JC; Tejedor, I; Tetart, F; Thill, C; Tordeur, CG	1

Reviews

1 review(s) available for ciclopirox and tacrolimus

Article	Year
Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. American journal of clinical dermatology, 2017, Volume: 18, Issue:2 Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Calcineurin Inhibitors; Ciclopirox; Dermatitis, Seborrheic; Dermatologic Agents; Desonide; Facial Dermatoses; Humans; Ketoconazole; Malassezia; Mometasone Furoate; Plant Preparations; Practice Guidelines as Topic; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Tacrolimus; Treatment Outcome; Vitamins	2017

Article

Year

Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review.

American journal of clinical dermatology, 2017, Volume: 18, Issue:2

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Calcineurin Inhibitors; Ciclopirox; Dermatitis, Seborrheic; Dermatologic Agents; Desonide; Facial Dermatoses; Humans; Ketoconazole; Malassezia; Mometasone Furoate; Plant Preparations; Practice Guidelines as Topic; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Tacrolimus; Treatment Outcome; Vitamins

2017

Trials

1 trial(s) available for ciclopirox and tacrolimus

Article	Year
Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study. Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:5 Topics: Adult; Ciclopirox; Dermatitis, Seborrheic; Double-Blind Method; Drug Administration Schedule; Facial Dermatoses; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Severity of Illness Index; Tacrolimus; Treatment Outcome	2021

Article

Year

Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study.

Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:5

Topics: Adult; Ciclopirox; Dermatitis, Seborrheic; Double-Blind Method; Drug Administration Schedule; Facial Dermatoses; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Severity of Illness Index; Tacrolimus; Treatment Outcome

2021

Other Studies

2 other study(ies) available for ciclopirox and tacrolimus

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression. Neuropharmacology, 2000, Jul-24, Volume: 39, Issue:10 Topics: Animals; Brain Ischemia; Cell Cycle; Ciclopirox; Dose-Response Relationship, Drug; Flavonoids; Growth Inhibitors; Male; Nerve Growth Factor; Neurites; PC12 Cells; Piperidines; Pyridones; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sirolimus; Tacrolimus	2000

Article

Year

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013

Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression.

Neuropharmacology, 2000, Jul-24, Volume: 39, Issue:10

Topics: Animals; Brain Ischemia; Cell Cycle; Ciclopirox; Dose-Response Relationship, Drug; Flavonoids; Growth Inhibitors; Male; Nerve Growth Factor; Neurites; PC12 Cells; Piperidines; Pyridones; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sirolimus; Tacrolimus

2000